Skip to Main content Skip to Navigation
Journal articles

IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients

Abstract : BACKGROUND: A very small proportion of patients diagnosed with glioblastoma (GBM) survive more than 3 years. Isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations define a small subgroup of GBM patients with favourable prognosis. However, it remains controversial whether long-term survivors (LTS) are found among those IDH1/2 mutated patients. METHODS: We retrospectively analyzed 207 GBM patients followed at Lariboisière Hospital (Paris) between 2005 and 2010. Clinical parameters were obtained from medical records. Mutations of IDH1/2 were analyzed in these patients, by immunohistochemistry for the R132H mutation of IDH1 and by high-resolution melting-curve analysis, followed by Sanger sequencing for IDH1 and IDH2 exon 4 mutations. Mutation rates in LTS and non-LTS groups were compared by Chi square Pearson test. RESULTS: Seventeen patients with survival \textgreater3 years were identified (8.2% of the total series). The median overall survival in long-term survivors was 4.6 years. Subgroup analysis found that the median age at diagnosis was significantly higher for non long-term survivors (non-LTS) compared to LTS (60 versus 51 years, p \textless0.03). The difference in the rate of IDH mutation between non-LTS and LTS was statistically not significant (1.16% versus 5.9%, p = 0.144). Among LTS, 10 out of 16 tumors presented a methylation of MGMT promoter. CONCLUSIONS: This study confirms that long-term survival in GBM patients is if at all only weakly correlated to IDH-mutation
Document type :
Journal articles
Complete list of metadatas
Contributor : Laurent Jonchère <>
Submitted on : Thursday, April 21, 2016 - 10:41:53 AM
Last modification on : Wednesday, October 14, 2020 - 3:59:03 AM

Links full text



Aymeric Amelot, Patricia de Cremoux, Véronique Quillien, Marc Polivka, Homa Adle-Biassette, et al.. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients. PLoS ONE, Public Library of Science, 2015, 10 (7), pp.e0130596. ⟨10.1371/journal.pone.0130596⟩. ⟨hal-01305489⟩



Record views